BCRX vs SPY Stock Comparison

SPY currently leads BCRX in this stock comparison, with AIQ scores of 63 vs 59. The clearest difference is momentum, while BCRX has the stronger value profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 4 points
BCRX
Healthcare
vs
SPY
Equity
BCRX
BioCryst Pharmaceuticals, Inc.
Price
$7.61
Day move
-0.91%
AIQ Score
59/100
Best edge
Value
Sector
Healthcare
SPY
State Street SPDR S&P 500 ETF
Leads
Price
$754
Day move
-0.36%
AIQ Score
63/100
Best edge
Momentum
Sector
Equity

What is the main difference between BCRX and SPY?

SPY leads the current stock comparison as State Street SPDR S&P 500 ETF, with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

BioCryst Pharmaceuticals, Inc. vs State Street SPDR S&P 500 ETF

Data as of Nov 15, 2026· market close· BCRX (stock) vs SPY (ETF)· Coverage 65/66 fields· 42/42 directly comparable· Moderate confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 5/10

SPY leads

SPY leads by 4 AIQ points, primarily on Momentum and Risk Resilience, but the lead has narrowed from 10 points over 30 sessions.

Competitive: 3 of 4 evidence groups support SPY, its lead is narrowing, and its signal state is cleanly positive.

Evidence agreement: 3 of 4Comparison trend: Weakening
BCRX

BioCryst Pharmaceuticals, Inc.

AIQ Score
59/100
AIQ Edge Score
6/10
SPY

State Street SPDR S&P 500 ETF

Leads
AIQ Score
63/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors SPY over BCRX, 63 versus 59 as of Nov 15, 2026. SPY's advantage is driven primarily by stronger momentum and risk resilience, while BCRX holds the stronger value profile. SPY also shows the stronger technical structure relative to its 50-day moving average. 3 of 4 covered evidence groups favor SPY today, and the comparison is rated Competitive on stability: the AIQ gap is narrow at 4 points. SPY lead: Weakening — the AIQ differential moved from 10 to 4 points over 30 sessions.

Compare BioCryst Pharmaceuticals, Inc. and State Street SPDR S&P 500 ETF across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BCRX
-36.6%
SPY
+72.3%

Total return comparison

Growth of $10,000, distributions reinvested

BCRX $6,336 · SPY $17,232

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BCRX and SPY against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BCRX advantage
0
SPY advantage
  • Value86 vs 37
    BCRX +49
  • Momentum42 vs 59
    SPY +17
  • Risk Resilience55 vs 72
    SPY +17
  • Quality64 vs 79
    SPY +15

3 of 4 evidence groups favor SPY. SPY’s edge is concentrated in momentum and risk resilience; BCRX keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

BCRX0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 4 active signals are unchanged.

SPY+1 AIQ

Largest factor move: Risk Resilience -1

No signal started or stopped since the prior session; its 5 active signals are unchanged.

SPY's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BCRX and SPY both carry a full feed there.

The central trade-off

SPY (State Street SPDR S&P 500 ETF): the stronger current systematic profile, led by momentum and risk resilience.

BCRX (BioCryst Pharmaceuticals, Inc.): the counter-case, on value, valuation — but at materially higher volatility, 45.2% against 22.1%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

SPY

SPY on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

Even

Growth figures are not covered for both names.

Value

BCRX

BCRX on the peer-relative Value factor, by 49 points.

Momentum

SPY

SPY on the Momentum factor, by 17 points.

Lower downside

SPY

SPY on Risk Resilience, by 17 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBCRXSPYNote
Implied upside to target+44.5%—Level
Target dispersion0%—Lower is tighter analyst agreement
ConsensusBuy—Context, not a primary driver
Analysts covering11—Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 4 covered evidence groups favor SPY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreSPY59 vs 63
FundamentalsNot coveredNot covered
ValuationBCRXValue 86 vs 37
TechnicalsSPYPrice vs 50-day -7.6% vs -1.3%; vs 200-day -13.5% vs 3.1%
Risk ResilienceSPYRisk Resilience 55 vs 72
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BCRX and SPY and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is narrow at 4 points. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader's signal state is cleanly positive. (supports the conclusion holding)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SPY.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

SPY lead: Weakening — the AIQ differential moved from 10 to 4 points over 30 sessions.

May 27BCRX leads above the line · SPY leads belowNov 13
Today
SPY +4
59 vs 63
7 sessions ago
SPY +3
62 vs 65
30 sessions ago
SPY +10
60 vs 70
90 sessions ago
BCRX +6
71 vs 65

The lead changed hands once in this window, most recently on Sep 15 when SPY moved ahead of BCRX.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BCRX

0 bullish / 2 bearish / 2 neutral

Only BCRX

  • Death Cross Active — bearish, trend, long horizon (6.91%)
  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.55%)
  • Downtrend Structure Active — bearish, trend, long horizon
SPY

2 bullish / 0 bearish / 3 neutral

Only SPY

  • Bollinger Band Squeeze — neutral, volatility, short horizon (5.9%)
  • Golden Cross Active — bullish, trend, long horizon (4.44%)
  • 52-Week High Proximity — bullish, risk_regime, long horizon (2.8%)
  • ATR Contraction - Coiling — neutral, volatility, short horizon (1.46%)

Both carry 1 more signal that do not separate them: ADX Trend Weakening.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BCRXNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.91%, AIQ 0 points).

SPYDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -0.36%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BCRX closes the Momentum gap — currently 17 points behind, the largest single contributor to SPY's edge.
  2. 2BCRX's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3SPY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
  4. 4The narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 4-point move would eliminate SPY's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricBCRXSPY
Revenue growth (YoY)-17.4%—
EPS growth (YoY)-51.6%—
Gross margin25.3%—
Operating margin-30.1%—
Return on equity (TTM)-9.5%—
Debt to equity-2.08—

Performance

SPY leads 6 of 6 windows
MetricBCRXSPY
1 week (5 sessions)-1%2.6%
1 month (20 sessions)-2.3%-1.2%
3 months (63 sessions)-23.4%-2.4%
6 months (126 sessions)-15.6%2.1%
Year to date-2.4%10.6%
1 year (252 sessions)6%10.4%

Technicals

SPY has the stronger structure
MetricBCRXSPY
RSI (14)40.747.1
ADX (14)15.214.2
Price vs 50-day-7.6%-1.3%
Price vs 200-day-13.5%3.1%
Volatility (1M, annualized)45.2%22.1%

Risk

SPY is the more resilient
MetricBCRXSPY
Beta0.651
Sharpe ratio0.360.63
Sortino ratio0.560.89
Max drawdown-32.2%-9.1%
Current drawdown-31.5%-3.2%
Annualized volatility48.1%13.6%
Value at risk (95%)-4.1%-1.4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BCRX or SPY?

On the Algovestiq AIQ Score, SPY is the stronger of the two as of Nov 15, 2026, scoring 63 against BCRX's 59. The edge comes from momentum and risk resilience. BCRX is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BCRX or SPY the better buy right now?

SPY carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 4 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor SPY over BCRX?

The composite weights Quality, Value, Momentum and Risk Resilience. BCRX leads Value by 49 points; SPY leads Momentum by 17 points; SPY leads Risk Resilience by 17 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BCRX or SPY?

Analyst price targets imply +44.5% upside for BCRX and not covered for SPY. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BCRX or SPY?

BCRX is the better-valued of the two on the peer-relative Value factor. BCRX on the peer-relative Value factor, by 49 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BCRX or SPY?

Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BCRX or SPY?

SPY on the Momentum factor, by 17 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BCRX or SPY?

SPY is the more resilient of the two, so the other name carries the higher downside risk. SPY on Risk Resilience, by 17 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BCRX more profitable than SPY?

Margin data is not comparable for both names in the current snapshot.

Is SPY's lead over BCRX getting stronger or weaker?

SPY lead: Weakening — the AIQ differential moved from 10 to 4 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-09-15, when SPY moved ahead of BCRX.

What would change the BCRX vs SPY verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BCRX closes the Momentum gap — currently 17 points behind, the largest single contributor to SPY's edge; BCRX's Death Cross Active resolves — a bearish trend rule currently active against it; SPY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 4-point move would eliminate SPY's advantage entirely.

What do the current signals say about BCRX and SPY?

BCRX: 0 bullish / 2 bearish / 2 neutral. SPY: 2 bullish / 0 bearish / 3 neutral. The most decision-relevant rule on BCRX is Death Cross Active (bearish, long horizon). On SPY it is Golden Cross Active (bullish, long horizon).

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.